...
search icon
biib-img

Biogen Inc Share Price

BIIB
NSQ
$195.62
-$0.9
(-0.46%)
1D
Industry: Biotechnology Sector: Health Care

Biogen Inc Analyst Forecast

Biogen Inc Share Price Chart

Biogen Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$28.84B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
22.3827
Volume info-icon
This is the total number of shares traded during the most recent trading day.
986.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.16
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$110.04 L
$202.41 H
$195.62

About Biogen Inc, Common Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Biogen Inc Stock Returns

Time FrameBIIBSectorS&P500
1-Week Return3.98%1.51%-1.5%
1-Month Return18.83%1.46%0.6%
3-Month Return19.33%3.94%2.43%
6-Month Return44.6%16.03%6.01%
1-Year Return43.9%9.1%11.48%
3-Year Return-29.41%19.46%67.52%
5-Year Return-28.97%35.29%73.75%
10-Year Return-26.02%137.42%254.46%

Biogen Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue10.98B10.17B9.84B9.68B9.81B[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.64,"profit":true},{"date":"2023-12-31","value":89.56,"profit":true},{"date":"2024-12-31","value":88.11,"profit":true},{"date":"2025-12-31","value":89.34,"profit":true}]
Cost of Revenue2.11B2.28B2.53B2.31B2.90B[{"date":"2021-12-31","value":72.82,"profit":true},{"date":"2022-12-31","value":78.64,"profit":true},{"date":"2023-12-31","value":87.45,"profit":true},{"date":"2024-12-31","value":79.75,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Profit8.87B7.90B7.30B7.37B6.91B[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":88.99,"profit":true},{"date":"2023-12-31","value":82.31,"profit":true},{"date":"2024-12-31","value":83.02,"profit":true},{"date":"2025-12-31","value":77.93,"profit":true}]
Gross Margin80.79%77.61%74.24%76.12%70.47%[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.06,"profit":true},{"date":"2023-12-31","value":91.9,"profit":true},{"date":"2024-12-31","value":94.22,"profit":true},{"date":"2025-12-31","value":87.23,"profit":true}]
Operating Expenses6.08B5.01B5.20B4.88B5.04B[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.33,"profit":true},{"date":"2023-12-31","value":85.6,"profit":true},{"date":"2024-12-31","value":80.18,"profit":true},{"date":"2025-12-31","value":82.82,"profit":true}]
Operating Income2.79B2.89B2.10B2.49B1.88B[{"date":"2021-12-31","value":96.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":72.59,"profit":true},{"date":"2024-12-31","value":86.2,"profit":true},{"date":"2025-12-31","value":64.99,"profit":true}]
Total Non-Operating Income/Expense(1.25B)548.00M(770.90M)(767.00M)(618.50M)[{"date":"2021-12-31","value":-228.81,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-140.68,"profit":false},{"date":"2024-12-31","value":-139.96,"profit":false},{"date":"2025-12-31","value":-112.86,"profit":false}]
Pre-Tax Income1.78B3.59B1.30B1.91B1.40B[{"date":"2021-12-31","value":49.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":36.08,"profit":true},{"date":"2024-12-31","value":53.03,"profit":true},{"date":"2025-12-31","value":38.99,"profit":true}]
Income Taxes52.50M632.80M135.30M273.80M108.11M[{"date":"2021-12-31","value":8.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":21.38,"profit":true},{"date":"2024-12-31","value":43.27,"profit":true},{"date":"2025-12-31","value":17.08,"profit":true}]
Income After Taxes1.73B2.96B1.16B1.63B1.29B[{"date":"2021-12-31","value":58.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.22,"profit":true},{"date":"2024-12-31","value":55.11,"profit":true},{"date":"2025-12-31","value":43.67,"profit":true}]
Income From Continuous Operations1.69B2.96B1.16B1.63B1.29B[{"date":"2021-12-31","value":57.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.22,"profit":true},{"date":"2024-12-31","value":55.11,"profit":true},{"date":"2025-12-31","value":43.66,"profit":true}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income1.56B3.05B1.16B1.63B1.29B[{"date":"2021-12-31","value":51.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.11,"profit":true},{"date":"2024-12-31","value":53.57,"profit":true},{"date":"2025-12-31","value":42.45,"profit":true}]
EPS (Diluted)19.1818.4515.0816.4715.29[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.19,"profit":true},{"date":"2023-12-31","value":78.62,"profit":true},{"date":"2024-12-31","value":85.87,"profit":true},{"date":"2025-12-31","value":79.72,"profit":true}]

Biogen Inc Ratios

Biogen Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

BIIB
Cash Ratio 1.14
Current Ratio 2.68
Quick Ratio 2.03

Biogen Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BIIB
ROA (LTM) 6.14%
ROE (LTM) 7.39%

Biogen Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BIIB
Debt Ratio Lower is generally better. Negative is bad. 0.38
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.62

Biogen Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BIIB
Trailing PE 22.38
Forward PE 12.52
P/S (TTM) 2.92
P/B 1.58
Price/FCF 62
EV/R 3.20
EV/Ebitda 12.14
PEG 1.28

FAQs

What is Biogen Inc share price today?

Biogen Inc (BIIB) share price today is $195.62

Can Indians buy Biogen Inc shares?

Yes, Indians can buy shares of Biogen Inc (BIIB) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIIB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Biogen Inc be purchased?

Yes, you can purchase fractional shares of Biogen Inc (BIIB) via the Vested app. You can start investing in Biogen Inc (BIIB) with a minimum investment of $1.

How to invest in Biogen Inc shares from India?

You can invest in shares of Biogen Inc (BIIB) via Vested in three simple steps:

  • Click on Sign Up or Invest in BIIB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Biogen Inc shares
What is Biogen Inc 52-week high and low stock price?

The 52-week high price of Biogen Inc (BIIB) is $202.41. The 52-week low price of Biogen Inc (BIIB) is $110.04.

What is Biogen Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Biogen Inc (BIIB) is 22.3827

What is Biogen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Biogen Inc (BIIB) is 1.58

What is Biogen Inc dividend yield?

The dividend yield of Biogen Inc (BIIB) is 0.00%

What is the Market Cap of Biogen Inc?

The market capitalization of Biogen Inc (BIIB) is $28.84B

What is Biogen Inc's stock symbol?

The stock symbol (or ticker) of Biogen Inc is BIIB

How Can Investors Use Biogen Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Biogen Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Biogen Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Biogen Inc shares for Indian investors?

When investing in Biogen Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Biogen Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Biogen Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Biogen Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Biogen Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top